It was the great British scientific triumph: an example of how big pharma can work altruistically for the good of the world, by making a vaccine available at cost price. But is the writing now on the wall for the AstraZeneca vaccine? This afternoon the European Medicines Agency (EMA) ruled that blood clots can be a ‘very rare side effect’ of the Oxford-AstraZeneca vaccine.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in